Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000058767 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intratumoural CD8 CXCR5 follicular cytotoxic T cells have prognostic value and are associated with CD19 CD38 B cells and tertiary lymphoid structures in colorectal cancer.
Cancer Immunol Immunother
December 2024
Department of Clinical Laboratory, State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: Colorectal cancer (CRC) is the most common digestive cancer in the world. Microsatellite stability (MSS) and microsatellite instability (MSI-high) are important molecular subtypes of CRC closely related to tumor occurrence and progression and immunotherapy efficacy. The presence of CD8 CXCR5 follicular cytotoxic T (T) cells is strongly associated with autoimmune disease and CD8 effector function.
View Article and Find Full Text PDFCausal association of circulating immune cells with nephrotic syndrome: evidence from a two-sample Mendelian randomization study.
Int Urol Nephrol
December 2024
Department of Emergency, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, 412007, China.
Objective: Nephrotic syndrome, a debilitating manifestation of kidney disease, often arises from diverse glomerular disorders and is accompanied by notable comorbidities. Despite indications of an immunological etiology, the precise role of immune cells in its pathogenesis remains unclear. This study aimed to elucidate the causal relationships between circulating immune cell phenotypes and nephrotic syndrome using a rigorous bidirectional Mendelian randomization approach.
View Article and Find Full Text PDFComplex causal relationships between genetic predictions of 731 immune cell phenotypes and novel coronavirus: A two-sample mendelian randomization analysis.
J Chin Med Assoc
December 2024
Department of Emergency Medicine, The Third Clinical Medical College of Ningxia Medical University, Ningxia, Yinchuan, China The Third Clinical Medical College of Ningxia Medical University, Ningxia,Yinchuan, China.
Background: COVID-19, caused by SARS-CoV-2, has had a significant impact on global health. While the virus primarily affects the respiratory system, the intricate interplay between immune cells and the virus remains poorly understood. This study investigates the causal relationship between 731 immune cell phenotypes and COVID-19 using Mendelian randomization analysis.
View Article and Find Full Text PDFMolecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia.
Hematol Oncol
January 2025
Hematology, Oncology R&D, AstraZeneca, Cambridge, UK.
Contemporary studies of Bruton tyrosine kinase inhibitor (BTKi) resistance focus on mutations in the B-cell receptor (BCR) pathway, but alternative mechanisms of resistance remain undefined. Here, we sought to identify novel predictive markers of acquired resistance to acalabrutinib, a second-generation BTKi, in patients with chronic lymphocytic leukemia (CLL). Clinical samples from 41 patients with relapsed/refractory or treatment-naive CLL receiving acalabrutinib as part of a clinical trial (NCT02029443) were divided into two groups: those who continued to respond to treatment (NP, n = 23) and those who developed progressive disease on acalabrutinib therapy (PD, n = 18).
View Article and Find Full Text PDFThe role of the JunD-RhoH axis in the pathogenesis of hairy cell leukemia and its ability to identify existing therapeutics that could be repurposed to treat relapsed or refractory disease.
Leuk Lymphoma
December 2024
Hematology CHU Caen Normandie, INSERM1245, MICAH, Normandie University of Caen and Rouen, UNIROUEN, UNICAEN, Hematology Institute, University Hospital Caen, Caen, France.
Hairy cell leukemia (HCL) is an indolent malignancy of mature B-lymphocytes. While existing front-line therapies achieve excellent initial results, a significant number of patients relapse and become increasingly treatment resistant. A major molecular driver of HCL is aberrant interlocking expression of the transcription factor JunD and the intracellular signaling molecule RhoH.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!